Off-Label Promotion Remains Vulnerable To Prosecution, Justice Department Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The information dissemination provisions in the FDA Modernization Act do not provide "carte blanche" for manufacturers to promote drugs off-label, the Department of Justice said in a recent letter to the Washington Legal Foundation